key: cord-0043768-i8jkzzmc authors: van der Zee, Philip; Rietdijk, Wim; Somhorst, Peter; Endeman, Henrik; Gommers, Diederik title: A systematic review of biomarkers multivariately associated with acute respiratory distress syndrome development and mortality date: 2020-05-24 journal: Crit Care DOI: 10.1186/s13054-020-02913-7 sha: 1312c7c565d3e51bd2ab5483170216f81e26d655 doc_id: 43768 cord_uid: i8jkzzmc BACKGROUND: Heterogeneity of acute respiratory distress syndrome (ARDS) could be reduced by identification of biomarker-based phenotypes. The set of ARDS biomarkers to prospectively define these phenotypes remains to be established. OBJECTIVE: To provide an overview of the biomarkers that were multivariately associated with ARDS development or mortality. DATA SOURCES: We performed a systematic search in Embase, MEDLINE, Web of Science, Cochrane CENTRAL, and Google Scholar from inception until 6 March 2020. STUDY SELECTION: Studies assessing biomarkers for ARDS development in critically ill patients at risk for ARDS and mortality due to ARDS adjusted in multivariate analyses were included. DATA EXTRACTION AND SYNTHESIS: We included 35 studies for ARDS development (10,667 patients at risk for ARDS) and 53 for ARDS mortality (15,344 patients with ARDS). These studies were too heterogeneous to be used in a meta-analysis, as time until outcome and the variables used in the multivariate analyses varied widely between studies. After qualitative inspection, high plasma levels of angiopoeitin-2 and receptor for advanced glycation end products (RAGE) were associated with an increased risk of ARDS development. None of the biomarkers (plasma angiopoeitin-2, C-reactive protein, interleukin-8, RAGE, surfactant protein D, and Von Willebrand factor) was clearly associated with mortality. CONCLUSIONS: Biomarker data reporting and variables used in multivariate analyses differed greatly between studies. Angiopoeitin-2 and RAGE in plasma were positively associated with increased risk of ARDS development. None of the biomarkers independently predicted mortality. Therefore, we suggested to structurally investigate a combination of biomarkers and clinical parameters in order to find more homogeneous ARDS phenotypes. PROSPERO IDENTIFIER: PROSPERO, CRD42017078957 The acute respiratory distress syndrome (ARDS) is a major problem in the intensive care unit (ICU) with a prevalence of 10% and an in-hospital mortality rate of 40% [1, 2] . ARDS pathophysiology is based on a triad of alveolar-capillary membrane injury, high permeability alveolar oedema, and migration of inflammatory cells [3] . This triad is not routinely measured in clinical practice. Therefore, arterial hypoxemia and bilateral opacities on chest imaging following various clinical insults are used as clinical surrogates in the American European Consensus Conference (AECC) definition and the newer Berlin definition of ARDS [4, 5] . Histologically, ARDS is characterized by diffuse alveolar damage (DAD). The correlation between a clinical and histological diagnosis of ARDS is poor [6] . Only half of clinically diagnosed patients with ARDS have histological signs of DAD at autopsy [7] [8] [9] [10] . The number of risk factors for ARDS and consequently the heterogeneous histological substrates found in patients with clinical ARDS have been recognized as a major contributor to the negative randomized controlled trial results among patients with ARDS [11] . It has been suggested that the addition of biomarkers to the clinical definition of ARDS could reduce ARDS heterogeneity by the identification of subgroups [12] [13] [14] [15] . A retrospective latent class analysis of large randomized controlled trials identified two ARDS phenotypes largely based on ARDS biomarkers combined with clinical parameters [16, 17] . These phenotypes responded differently to the randomly assigned intervention arms. Prospective studies are required to validate these ARDS phenotypes and their response to interventions. The set of ARDS biomarkers to prospectively define these phenotypes remains to be established. Numerous biomarkers and their pathophysiological role in ARDS have been described [12, 18] . In an earlier meta-analysis, biomarkers for ARDS development and mortality were examined in univariate analysis [19] . However, pooling of univariate biomarker data may result in overestimation of the actual effect. For this reason, we conducted a systematic review and included all biomarkers that were multivariately associated with ARDS development or mortality. This study provides a synopsis of ARDS biomarkers that could be used for future research in the identification of ARDS phenotypes. This systematic review was prospectively registered in PROSPERO International Prospective Register of Systematic Reviews (PROSPERO identifier CRD42017078957) and performed according to the Transparent Reporting of Systematic Reviews and Meta-analyses (PRISMA) Statement [20] . After the search strategy, two reviewers (PZ, PS, and/or WG) separately performed study eligibility criteria, data extraction, and quality assessment. Any discrepancies were resolved by consensus, and if necessary, a third reviewer was consulted. We searched for studies that included biomarkers that were associated with ARDS development in critically ill patients at risk for ARDS and mortality in the ARDS population in multivariate analyses adjusted for background characteristics. We did not perform a metaanalysis, because the raw data in all studies was either not transformed or log transformed resulting in varying risk ratios and confidence intervals. In addition, the majority of studies used different biomarker concentration cut-offs, resulting in varying concentration increments for risk ratios. Lastly, the number of days until mortality and variables used in multivariate analysis differed between studies. For these reasons, we limited this study to a systematic review, as the multivariate odds ratios were not comparable and pooling would result in noninformative estimates [21] . We performed a systematic search in Embase, MED-LINE, Web of Science, Cochrane CENTRAL, and Google Scholar from inception until 30 July 2018 with assistance from the Erasmus MC librarian. The search was later updated to 6 March 2020. A detailed description of the systematic search string is presented in Additional file 1. In addition, the reference lists of included studies and recent systematic reviews were screened to identify additional eligible studies. All retrieved studies were screened on the basis of title and abstract. Studies that did not contain adult patients at risk for ARDS or with ARDS and any biomarker for ARDS were excluded. The following eligibility criteria were used: human research, adult population, studies in which biomarkers were presented as odds ratios (OR) or risk ratios in multivariate analysis with ARDS development or mortality as outcome of interest, peer-reviewed literature only, and English language. Studies comparing ARDS with healthy control subjects, case series (< 10 patients included in the study), and studies presenting gene expression fold change were excluded. A standardized form was used for data extraction from all eligible studies. Two clinical endpoints were evaluated in this study: development of ARDS in the at-risk population (patients that did develop ARDS versus critically ill patients that did not) and mortality in the ARDS population (survivors versus non-survivors). The following data were extracted: study design and setting, study population, sample size, the definition of ARDS used in the study, outcome, risk ratio with 95% confidence interval in multivariate analyses, and the variables used in the analyses. In addition, the role of the biomarker in ARDS pathophysiology as reported by the studies was extracted and divided into the following categories: increased endothelial permeability, alveolar epithelial injury, oxidative injury, inflammation, pro-fibrotic, myocardial strain, coagulation, and others. Subsequently, the relative frequency distribution of biomarker roles in ARDS pathophysiology was depicted in a bar chart. Methodological quality of the included studies was assessed with the Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in systematic reviews and meta-analyses [22] . Items regarding patient selection, comparability, and outcome were assessed using a descriptive approach, and a risk-of-bias score, varying between 0 (high risk) and 9 (low risk), was assigned to each study. A total of 8125 articles were identified by the initial search and 972 by the updated search (Fig. 1) . After removal of duplicates and reviewing titles and abstracts, we selected 438 articles for full-text review. A total of 86 studies was eligible for data extraction: 35 for ARDS development and 53 for ARDS mortality. The study characteristics of the 35 studies for ARDS development are presented in Table 1 . A total of 10,667 critically ill patients was at risk for ARDS, of whom 2419 (24.6%) patients developed ARDS. The majority of Table 2 . A total of 15,344 patients with ARDS were included with an observed mortality rate of 36.0%. The AECC definition of ARDS was used in the majority of included studies (39/53). The included biomarkers were measured in plasma, bronchoalveolar lavage fluid, and urine. All samples were taken within 72 h following the development of ARDS. The median quality of the included publications according to the NOS was 7 (range 4-9) for ARDS A total of 37 biomarkers in plasma, 7 in cerebrospinal fluid, and 1 in bronchoalveolar lavage fluid were assessed in multivariate analyses (Table 3) . Five studies examined angiopoeitin-2 (Ang-2) and seven studies examined receptor for advanced glycation end products (RAGE). In all studies, high plasma levels of Ang-2 and RAGE were significantly associated with an increased risk of ARDS development in the at-risk population. Similar results were seen for surfactant protein D (SpD) in plasma in all three studies that assessed SpD. In contrast, biomarkers for inflammation as C-reactive protein (CRP), procalcitonin, interleukin-6, and interleukin-8 were not clearly associated with ARDS development. The majority of biomarkers in plasma are surrogates for inflammation in ARDS pathophysiology (Fig. 2) . A total of 49 biomarkers in plasma, 8 in bronchoalveolar lavage fluid, and 3 in urine were included in this study (Table 4) . Ang-2, CRP, interleukin-8 (IL-8), RAGE, SpD, and Von Willebrand factor (VWF) in plasma were assessed in four or more studies. However, none of these biomarkers was associated with ARDS mortality in all four studies. Similarly to biomarkers in ARDS development, the majority of biomarkers for ARDS mortality in plasma had a pathophysiological role in inflammation (Fig. 2) . The majority of biomarkers measured in bronchoalveolar lavage fluid had a pro-fibrotic role in ARDS pathophysiology. In the current systematic review, we present a synopsis of biomarkers for ARDS development and mortality tested in multivariate analyses. We did not perform a meta-analysis because of severe data heterogeneity between studies. Upon qualitative inspection, we found that high levels of Ang-2 and RAGE were associated with ARDS development in the at-risk population. None of the biomarkers assessed in four or more studies was associated with an increased mortality rate in all studies. The majority of plasma biomarkers for both ARDS development and mortality are surrogates for inflammation in ARDS pathophysiology. Previously, Terpstra et al. [19] calculated univariate ORs from absolute biomarker concentrations and performed a meta-analysis. They found that 12 biomarkers in plasma were associated with mortality in patients with ARDS. However, a major limitation of their metaanalysis is that these biomarkers were tested in univariate analyses without considering confounders as disease severity scores. Given the high univariate ORs as compared to the multivariate ORs found in this systematic review, the performance of these biomarkers is likely to be overestimated. Jabaudon et al. [109] found in an individual patient data meta-analysis that high concentrations of plasma RAGE were associated with 90-day mortality independent of driving pressure or tidal volume. However, they could not correct for disease severity score as these differed between studies. Unfortunately, we were unable to perform a meta-analysis on multivariate data because of heterogeneity of the included studies, as transformation of raw data, biomarker concentration cut-offs, time until outcome, and the variables used in the multivariate analyses varied widely between studies. This could be an incentive to standardize the presentation of ARDS biomarker research in terms of statistics and outcome for future analyses or to make individual patient data accessible. ARDS biomarkers are presumed to reflect the pathophysiology of ARDS, characterized by alveolar-capillary membrane injury, high permeability alveolar oedema, and migration of inflammatory cells [3] . Previously, Terpstra et al. [19] proposed that biomarkers for ARDS development were correlated with alveolar tissue injury, whereas biomarkers for ARDS mortality correlated more with inflammation. In this systematic review, we found that the majority of biomarkers tested for both ARDS development and mortality were surrogates for inflammation. However, following qualitative inspection, biomarkers for inflammation were not evidently associated with either ARDS development or mortality. In contrast, markers for alveolar epithelial injury (plasma RAGE and SpD) and endothelial permeability (plasma Ang-2) seem to be associated with ARDS development. Therefore, we should consider how we intend to use (a set of) biomarkers in patients with ARDS. A biomarker for ARDS development should be specific for ARDS, i.e. a biomarker that reflects alveolar injury or alveolar-capillary injury. Half of plasma biomarkers for ARDS development included in this study reflected inflammation. An increase in inflammatory biomarkers is known to correlate with increased disease severity scores [71, 97, 110] . In turn, the majority of studies in this review found significantly higher disease severity scores in the critically ill patients that eventually developed ARDS. Thus, plasma biomarkers for inflammation rather represented an estimation of disease severity and its associated increased risk for the development of ARDS. In addition, biomarkers for inflammation in plasma lack the specificity to diagnose ARDS, as they are unlikely to differentiate sepsis with ARDS from sepsis without ARDS. In contrast, locally sampled biomarkers for inflammation, for example in the alveolar space, could potentially diagnose ARDS [111] . Biomarkers used for ARDS mortality or for the identification of less heterogeneous ARDS phenotypes do not require to be ARDS specific, provided that they adequately predict or stratify patients with ARDS. The heterogeneity of ARDS has been recognized as a major contributor to the negative randomized controlled trial results among patients with ARDS [11] . Therefore, it is necessary to identify homogeneous ARDS phenotypes that are more likely to respond to an intervention. This is known as predictive enrichment [112] . Previously, patients with ARDS have been successfully stratified based on clinical parameters, such as ARDS risk factor (pulmonary or extra-pulmonary) or PaO 2 /FiO 2 ratio [113] . ARDS biomarkers could be used to stratify patients with ARDS based on biological or pathophysiological phenotype. For example, trials of novel therapies designed to influence vascular permeability may benefit from preferentially enrolling patients with high Ang-2 concentrations. Recently, clinical parameters have been combined with a set of biomarkers in a retrospective latent class analysis. In three trials, two distinct phenotypes were found: hyperinflammatory and hypoinflammatory ARDS [16, 17] . Patients with the hyperinflammatory phenotype had reduced mortality rate with higher positive end-expiratory pressures and with liberal fluid treatment, whereas the trials themselves found no difference between the entire intervention groups. The next step is to validate the identification of ARDS phenotypes based on latent class analysis in prospective studies. An adequate combination of biomarkers and clinical parameters remains to be established. Until now, there is no list of biomarkers that are associated with ARDS development or mortality independently of clinical parameters. This systematic review may guide the selection of ARDS biomarkers used for predictive enrichment. This systematic review has limitations. First, the intent of this systematic review was to perform a meta-analysis. However, we decided not to perform a meta-analysis, as the biomarker data handling and outcomes varied widely among studies, and pooling would have resulted in a non-informative estimate [21] . Arguably, this is a positive result, as it refrains us from focusing on the few biomarkers that could be pooled in a meta-analysis and guides us into a direction were multiple biomarkers combined with other parameters are of interest. In a heterogeneous syndrome as ARDS, the one biomarker probably does not exist. Second, the first sampling moment varied between sampling at ICU admission until 72 h following ICU admission. Initially, ARDS is characterized by an exudative phase followed by a second proliferative phase and late fibrotic phase [3] . The moment of sampling likely influences biomarker concentrations, as both alveolar membrane injury and inflammation increase during the exudative phase. This is also seen in six biomarkers that have been measured at separate days, resulting in a significant change in adjusted OR for four biomarkers (Table 4) [61, 98, 104, 105] . Third, the aim of this systematic review was to assess the independent risk effects of biomarkers measured in various bodily fluid compartments. However, the majority of studies assessed biomarkers in plasma. It remains to be answered whether other bodily fluid compartments, for example from the airways and alveolar space themselves, might outperform ARDS biomarkers in plasma, especially for ARDS development. Fourth, all studies found in this systematic review used a clinical definition of ARDS as standard for ARDS diagnosis. Given the poor correlation between a clinical diagnosis and a histopathological diagnosis of ARDS, these studies are diagnosing a very heterogeneous disease syndrome [7] [8] [9] [10] . In order to actually evaluate ARDS development, biomarkers should be compared to a histopathological image of DAD, although acquiring histology poses great challenges by itself. Fifth, as only biomarkers assessed in multivariate analyses were included in this study, new promising biomarkers evaluated in univariate analyses were excluded from this study. Lastly, non-significant biomarkers in multivariate analyses were more likely not to be reported, although some studies report nonsignificant results nonetheless. In here, we present a list of biomarkers for ARDS mortality and ARDS development tested in multivariate analyses. In multiple studies that assessed Ang-2 and RAGE, high plasma levels were associated with an increased risk of ARDS development. We did not find a biomarker that independently predicted mortality in all studies that assessed the biomarker. Furthermore, biomarker data reporting and variables used in multivariate analyses differed greatly between studies. Taken together, we should look for a combination of biomarkers and clinical parameters in a structured approach in order to find more homogeneous ARDS phenotypes. This systematic review may guide the selection of ARDS biomarkers for ARDS phenotyping. Supplementary information accompanies this paper at https://doi.org/10. 1186/s13054-020-02913-7. Past and present ARDS mortality rates: a systematic review Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries Acute respiratory distress syndrome The American-European consensus conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination Acute respiratory distress syndrome: the Berlin definition Pulmonary pathology of acute respiratory distress syndrome ARDS: a clinicopathological confrontation Diffuse alveolar damage associated mortality in selected acute respiratory distress syndrome patients with open lung biopsy Acute respiratory distress syndrome in patients with and without diffuse alveolar damage: an autopsy study Frutos-Vivar F. Comparison of the Berlin definition for acute respiratory distress syndrome with autopsy Clinical trials in acute respiratory distress syndrome: challenges and opportunities Biomarkers for the acute respiratory distress syndrome: how to make the diagnosis more precise GOLDEN anniversary of the acute respiratory distress syndrome: still much work to do! Curr Opin Crit Care ARDS: progress unlikely with non-biological definition Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy A pathophysiologic approach to biomarkers in acute respiratory distress syndrome Plasma biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis* The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Systematic reviews in health care: meta-analysis in context The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients IGF1 and IGFBP3 in acute respiratory distress syndrome Plasma cytokines IL-6, IL-8, and IL-10 are associated with the development of acute respiratory distress syndrome in patients with severe traumatic brain injury Evolution of leukotriene B4, peptide leukotrienes, and interleukin-8 plasma concentrations in patients at risk of acute respiratory distress syndrome and with acute respiratory distress syndrome: mortality prognostic study Dramatic increases in blood glutamate concentrations are closely related to traumatic brain injury-induced acute lung injury Blood Glutamate Levels Are Closely Related to Acute Lung Injury and Prognosis after Stroke Serum plasminogen activator urokinase receptor predicts elevated risk of acute respiratory distress syndrome in patients with sepsis and is positively associated with disease severity, inflammation and mortality Plasma level of advanced oxidation protein products as a novel biomarker of acute lung injury following cardiac surgery Plasma mitochondrial DNA levels are associated with ARDS in trauma and sepsis patients Acute lung injury in patients with traumatic injuries: utility of a panel of biomarkers for diagnosis and pathogenesis Low endocan levels are predictive of acute respiratory distress syndrome in severe sepsis and septic shock Elevated plasma levels of TIMP-3 are associated with a higher risk of acute respiratory distress syndrome and death following severe isolated traumatic brain injury High expression of long non-coding RNA MALAT1 correlates with raised acute respiratory distress syndrome risk, disease severity, and increased mortality in sepstic patients Immature granulocytes: a novel biomarker of acute respiratory distress syndrome in patients with acute pancreatitis Receptor for advanced glycation end-products and ARDS prediction: a multicentre observational study Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial Plasma sRAGE acts as a genetically regulated causal intermediate in sepsis-associated acute respiratory distress syndrome Diagnostic utility of C-reactive protein combined with brain natriuretic peptide in acute pulmonary edema: a cross sectional study Pre-B-cell colony-enhancing factor and its clinical correlates with acute lung injury and sepsis Diagnostic and prognostic values of Club cell protein 16 (CC16) in critical care patients with acute respiratory distress syndrome Elevation of Serum PARK7 and IL-8 Levels Is Associated With Acute Lung Injury in Patients With Severe Early identification of patients at risk for acute respiratory distress syndrome among severe pneumonia: a retrospective cohort study Myeloperoxidase-derived 2-chlorofatty acids contribute to human sepsis mortality via acute respiratory distress syndrome Lower serum endocan levels are associated with the development of acute lung injury after major trauma Soluble endothelial selectin in acute lung injury complicated by severe pneumonia Low Plasma Levels of Adiponectin Do Not Explain Acute Respiratory Distress Syndrome Risk: a Prospective Cohort Study of Patients with Severe Sepsis Plasma angiopoietin-2 as a potential causal marker in sepsis-associated ARDS development: evidence from Mendelian randomization and mediation analysis Plasma receptor interacting protein kinase-3 levels are associated with acute respiratory distress syndrome in sepsis and trauma: a cohort study Circulating microparticle levels are reduced in patients with ARDS Soluble thrombomodulin in bronchoalveolar lavage fluid is an independent predictor of severe druginduced lung injury Long non-coding RNA THRIL predicts increased acute respiratory distress syndrome risk and positively correlates with disease severity, inflammation, and mortality in sepsis patients Derivation and validation of a two-biomarker panel for diagnosis of ARDS in patients with severe traumatic injuries. Trauma Surg Acute Care Open Predictive value of combined LIPS and ANG-2 level in critically ill patients with ARDS risk factors Elevated plasma levels of Gas6 are associated with acute lung injury in patients with severe sepsis Endocan, a Risk Factor for Developing Acute Respiratory Distress Syndrome among Severe Pneumonia Patients An increased alveolar CD4 + CD25 + Foxp3 + T-regulatory cell ratio in acute respiratory distress syndrome is associated with increased 30-day mortality Prognostic value of plasma N-terminal probrain natriuretic peptide levels in the acute respiratory distress syndrome Plasma C-reactive protein levels are associated with improved outcome in ARDS Prognostic and diagnostic value of plasma soluble suppression of tumorigenicity-2 concentrations in acute respiratory distress syndrome Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury Soluble intercellular adhesion molecule-1 and clinical outcomes in patients with acute lung injury Use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injury Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance Distinct molecular phenotypes of direct vs indirect ARDS in singlecenter and multicenter studies Predictive value of plasma biomarkers for mortality and organ failure development in patients with acute respiratory distress syndrome Decoy receptor 3 levels in peripheral blood predict outcomes of acute respiratory distress syndrome Type III procollagen peptide in the adult respiratory distress syndrome. Association of increased peptide levels in bronchoalveolar lavage fluid with increased risk for death Growth differentiation factor-15 and prognosis in acute respiratory distress syndrome: a retrospective cohort study Inflammasomeregulated cytokines are critical mediators of acute lung injury Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury Type III procollagen is a reliable marker of ARDS-associated lung fibroproliferation Transforming Growth Factor-β1 in predicting early lung fibroproliferation in patients with acute respiratory distress syndrome High levels of circulating leukocyte microparticles are associated with better outcome in acute respiratory distress syndrome Diagnostic and prognostic values of serum activin-a levels in patients with acute respiratory distress syndrome Serum uric acid level as a prognostic marker in patients with acute respiratory distress syndrome Outcome value of Clara cell protein in serum of patients with acute respiratory distress syndrome The association between the neutrophil-tolymphocyte ratio and mortality in patients with acute respiratory distress syndrome: a retrospective cohort study Serum soluble triggering receptor expressed on myeloid cells-1 in acute respiratory distress syndrome: a prospective observational cohort study Copeptin in the assessment of acute lung injury and cardiogenic pulmonary edema Increased plasma levels of heparinbinding protein in patients with acute respiratory distress syndrome Elevated transforming growth factor-α levels in bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome Higher urine desmosine levels are associated with mortality in patients with acute lung injury Higher urine nitric oxide is associated with improved outcomes in patients with acute lung injury Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury Nucleated red blood cells as predictors of mortality in patients with acute respiratory distress syndrome (ARDS): an observational study Prevalence and prognostic association of circulating troponin in the acute respiratory distress syndrome Elevated plasma levels of sRAGE are associated with nonfocal CT-based lung imaging in patients with ARDS: a prospective multicenter study Ratio of angiopoietin-2 to angiopoietin-1 as a predictor of mortality in acute lung injury patients Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury Alveolar fibrocyte percentage is an independent predictor of poor outcome in patients with acute lung injury Increased circulating microRNA-122 is associated with mortality and acute liver injury in the acute respiratory distress syndrome Circulating angiotensin peptides levels in Acute Respiratory Distress Syndrome correlate with clinical outcomes: A pilot study Prognostic significance of elevated cardiac troponin-T levels in acute respiratory distress syndrome patients Association of elevated plasma interleukin-18 level with increased mortality in a clinical trial of statin treatment for acute respiratory distress syndrome Plasma soluble thrombomodulin levels are associated with mortality in the acute respiratory distress syndrome Plasma granulocyte colonystimulating factor levels correlate with clinical outcomes in patients with acute lung injury Endocan levels in peripheral blood predict outcomes of acute respiratory distress syndrome The impact of the PAI-1 4G/5G polymorphism on the outcome of patients with ALI/ARDS Angiopoietin-2 Levels as Predictors of Outcome in Mechanically Ventilated Patients with Acute Respiratory Distress Syndrome Effect of angiotensin converting enzyme gene I/D polymorphism and its expression on clinical outcome in acute respiratory distress syndrome Impact of serum biomarkers and clinical factors on intensive care unit mortality and 6-month outcome in relatively healthy patients with severe pneumonia and acute respiratory distress syndrome Plasma neutrophil elastase and Elafin as prognostic biomarker for acute respiratory distress syndrome: a multicenter survival and longitudinal prospective observation study Neutrophil-to-lymphocyte ratio as a prognostic marker in acute respiratory distress syndrome patients: a retrospective study Significance of Von Willebrand factor in septic and nonseptic patients with acute lung injury The predictive value of plasma galectin-3 for ARDS severity and clinical outcome Plasma sRAGE is independently associated with increased mortality in ARDS: a meta-analysis of individual patient data Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity Cytokines and chemokines are detectable in swivel-derived exhaled breath condensate (SEBC): a pilot study in mechanically ventilated patients Toward smarter lumping and smarter splitting: rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design Phenotypes in acute respiratory distress syndrome: moving towards precision medicine Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations We thank Wan-Jie Gu (abbreviated in the text as WG) for his support in study eligibility evaluation (Nanjing University, China). We thank Wichor Bramer and Elise Krabbendam (Biomedical Information Specialists Medical Library Erasmus MC) for their support in the literature search. Authors' contributions PZ collected and analysed the data and drafted the manuscript. WR analysed the data and substantially revised the manuscript. PS collected the data and substantially revised the manuscript. HE and DG substantially revised the manuscript. The authors read and approved the final manuscript. Availability of data and materials The datasets used during the current study are available from the corresponding author on reasonable request.